Metachronous Double Primary Gastric and Colorectal Cancer: Is Prognosis Better with Gastric or Colorectal Cancer Occurring First?


The purpose of this study was to investigate the clinicopathological features of gastric precedence (GP) and colorectal precedence (CP) metachronous double primary gastric and colorectal cancer (MDPGCC) and determine the biological significance of these two types of malignancy in making a prognosis. Between January 1990 and December 2009, 4523 patients underwent surgical treatment or chemotherapy, but no endoscopic resection for gastric or colorectal cancer. From this group, we selected those patients in whom another gastric or colorectal primary cancer developing from another origin had been diagnosed. For classification as MDPGCC there had to be an interval of 6 months or more before a secondary diagnosis of gastric or colorectal cancer. Among 4523 patients treated for gastric or colorectal cancer, MDPGCC was diagnosed in 54 patients (1.2%). The selected patients were classified into a GP (n = 30) or CP group (n = 24). No statistically significant differences were observed between the two groups with regard to sex, age, operation, location or histological type. No differences were observed in rates of surgery between the two groups. No notable difference was observed in the year-by-year incidence of GP- and CP-MDPGCC as calculated from the date of surgery or chemotherapy for the secondary gastric or colorectal cancer. The 5-year survival rate in the GP- and CP-MDPGCC groups was 84.7% and 83.3%, respectively. No significant difference was observed between the GP- and CP-MDPGCC groups (P = 0.9). There is no significant difference in prognosis between GP- and CP-MDPGCC.

Share and Cite:

M. Kochi, M. Fujii, N. Kanamori, Y. Mihara, T. Funada, H. Tamegai, M. Watanabe, Y. Takayama, H. Suda and T. Takayama, "Metachronous Double Primary Gastric and Colorectal Cancer: Is Prognosis Better with Gastric or Colorectal Cancer Occurring First?," Journal of Cancer Therapy, Vol. 4 No. 3, 2013, pp. 720-725. doi: 10.4236/jct.2013.43088.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] W. Haenszel, F. B. Locke and M. Segi, “A Case-Control Study of Large Bowel Cancer in Japan,” Journal of the National Cancer Institute, Vol. 64, No. 1, 1980, pp. 17-22.
[2] B. Armstrong and R. Doll, “Environmental Factors and Cancer Incidence and Mortality in Different Countries, with Special Reference to Dietary Practices,” International Journal of Cancer, Vol. 15, No. 4, 1975, pp. 617-663. doi:10.1002/ijc.2910150411
[3] B. W. Eom, H.-J. Lee, M.-W. Yoo, J. J. Cho, W. H. Kim, H.-K. Yang and K. U. Lee, “Synchronous and Metachronous Cancers in Patients with Gastric Cancer,” Journal of Surgical Oncology, Vol. 1, No. 98, 2008, pp. 106-110. doi:10.1002/jso.21027
[4] Y. Ikeda, M. Saku, H. Kawanaka, M. Nonaka and K. Yoshida, “Features of Second Primary Cancer in Patients with Gastric Cancer,” Oncology, Vol. 65, No. 2, 2003, pp. 113-117. doi:10.1159/000072335
[5] Y. Maehara, S. Tomisaki, Y. Emi, Y. Sakaguchi, T. Kusumoto, Y. Ichiyoshi and K. Sugimachi, “Clinicopathological Features of Patients Who Died with Second Primary Cancer after Curative Resection for Gastric Cancer,” Anticancer Research, Vol. 15, No. 3, 1995, pp. 1049-1053.
[6] H. Furukawa, M. Hiratsuka, T. Iwanaga, S. Imaoka, T. Kabuto, O. Ishikawa, Y. Sasaki, M. Kameyama, H. Ohigashi and S. Nakamori, “Treatments for Second Malignancies after Gastrectomy for Stomach Cancer,” Hepatogastroenterology, Vol. 43, No. 7, 1996, pp. 194-198.
[7] M. Watanabe, M. Kochi, M. Fujii, T. Kaiga, Y. Mihara, T. Funada, H. Tamegai, H. Shimizu and T. Takayama, “Double Primary Gastric and Colorectal Cancer: Is the Better Prognosis Synchronous or Metachronous?” American Journal of Clinical Oncology, Vol. 35, No. 5, 2012, pp. 407-410. doi:10.1097/COC.0b013e318218585a
[8] C. W. Wu, S. S. Lo, J. H. Chen, M. C. Hsieh, A. F. Li and W. Y. Lui, “Multiple Primary Cancers in Patients with Gastric Cancer ” Hepatogastroenterology, Vol. 53, No. 69, 2006, pp. 463-467.
[9] G. Lundeg?rdh, L. E. Hansson, O. Nyrén, H. O. Adami and U. B. Krusemo, “The Risk of Gastrointestinal and Other Primary Malignant Diseases Following Gastric Cancer ” Acta Oncologica, Vol. 30, No. 1, 1991, pp. 1-6. doi:10.3109/02841869109091804
[10] J. H. Lee, J. S. Bae, K. W. Ryu, J. S. Lee, S. R. Park, C. G. Kim, M. C. Kook, I. J. Choi, Y. W. Kim, J. G. Park and J. M. Bae, “Gastric Cancer Patients at High-Risk of Having Synchronous Cancer,” World Journal of Gastroenterology, Vol. 28, No. 12, 2006, pp. 2588-2592.
[11] M. Ikeguchi, S. Ohfuji, A. Oka, S. Tsujitani, M. Maeda and N. Kaibara, “Synchronous and Metachronous Primary Malignancies in Organs Other than the Stomach in Patients with Early Gastric Cancer,” Hepatogastroenterology, Vol. 42, No. 5, 1995, pp. 672-676.
[12] JSCCR, “Japanese Society for Cancer of the Colon and Rectum (JSCCR) Colon and Rectum Treatment Guidelines,” Kanehara & Co. Ltd., Tokyo, 2009.
[13] S. Saito, Y. Hosoya, K. Togashi, K. Kurashina, H. Haruta, M. Hyodo, K. Koinuma, H. Horie, Y. Yasuda and H. Nagai, “Prevalence of Synchronous Colorectal Neoplasms Detected by Colonoscopy in Patients with Gastric Cancer,” Surgery Today, Vol. 38, No. 1, 2008, pp. 20-25.
[14] N. Kaibara, M. Maeta and M. Ikeguchi, “Patients with Multiple Primary Gastric Cancers Tend to Develop Second Primaries in Organs Other than the Stomach,” Surgery Today, Vol. 23, No. 2, 1993, pp. 186-188. doi:10.1007/BF00311241
[15] M. Ueno, T. Muto, M. Oya, H. Ota, K. Azekura and T. Yamaguchi, “Multiple Primary Cancer: An Experience at the Cancer Institute Hospital with Special Reference to Colorectal Cancer,” International Journal of Clinical Oncology, Vol. 8, No. 3, 2003, pp. 162-167. doi:10.1007/s10147-003-0322-z
[16] Japanese Gastric Cancer Association, “Japanese Gastric Cancer Treatment Guideline 2010 (ver. 3),” Gastric Cancer, Vol. 14, No. 2, 2011, pp. 113-123. doi:10.1007/s10120-011-0042-4
[17] W. Koizumi, H. Narahara, T. Hara, A. Takagane, T. Akiya, M. Takagi, K. Miyashita, T. Nishizaki, O. Kobayashi, W. Takiyama, Y. Toh, T. Nagaie, S. Takagi, Y. Yamamura, K. Yanaoka, H. Orita and M. Takeuchi, “S-1 plus Cisplatin versus S-1 Alone for First-Line Treatment of Advanced Gastric Cancer (SPIRITS trial): A Phase III Trial,” The Lancet Oncology, Vol. 9, No. 3, 2008, pp. 215-221. doi:10.1016/S1470-2045(08)70035-4
[18] G. Colucci, V. Gebbia, G. Paoletti, F. Giuliani, M. Caruso, N. Gebbia, G. Cartenì, B. Agostara, G. Pezzella, L. Manzione, N. Borsellino, A. Misino, S. Romito, E. Durini, S. Cordio, M. Di Seri, M. Lopez, E. Maiello, S. Montemurro, A. Cramarossa, V. Lorusso, M. Di Bisceglie, M. Chiarenza, M. R. Valerio, T. Guida, V. Leonardi, S. Pisconti, G. Rosati, F. Carrozza, G. Nettis, M. Valdesi, G. Filippelli, S. Fortunato, S. Mancarella, C. Brunetti and Gruppo Oncologico Dell’Italia Meridionale, “Phase III Randomized Trial of FOLFIRI versus FOLFOX4 in the Treatment of Advanced Colorectal Cancer: A Multicenter Study of the Gruppo Oncologico Dell’Italia Meridionale,” Journal of Clinical Oncology, Vol. 1, No. 23, 2005, pp. 4866-4875. doi:10.1200/JCO.2005.07.113

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.